CN105214341B - combined adsorption column and preparation method thereof - Google Patents
combined adsorption column and preparation method thereof Download PDFInfo
- Publication number
- CN105214341B CN105214341B CN201510595440.0A CN201510595440A CN105214341B CN 105214341 B CN105214341 B CN 105214341B CN 201510595440 A CN201510595440 A CN 201510595440A CN 105214341 B CN105214341 B CN 105214341B
- Authority
- CN
- China
- Prior art keywords
- aglucon
- adsorption column
- adsorbent
- adsorbents
- additional adsorbents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of combined adsorption column and preparation method thereof.The combined adsorption column includes cylinder and the main adsorbent and additional adsorbents that are filled in the cylinder, the main adsorbent is used to adsorb the target substance in blood, the additional adsorbents are used to adsorb the aglucon that the main adsorbent drops, and the aglucon of the additional adsorbents derives from the target substance or its part.When carrying out immunoadsorption therapy using the adsorption column, while morbid substance in removing blood, it can effectively reduce the aglucon to come off and enter the risk of blood, while other risk factors will not be introduced.
Description
Technical field
The present invention relates to medical instruments field, more particularly to a kind of combined adsorption column and preparation method thereof.
Background technology
Immuno absorbence therapy is a kind of new technology to grow up in the past 30 years, is difficult to play for treating some conventional methods
The disease of effect.It is combined antigen, antibody or other materials with specific physical chemistry affinity as part with carrier, system
Into immunoabsorbent column, using its specific adsorption performance, the virulence factor in selective clearing blood samples of patients, so as to reach purification
Blood, the purpose for alleviating the state of an illness.It can clinically be treated more by specifically removing autoantibody using immuno absorbence at present
Kind of autoimmune disease and organ transplant rejection, and by adsorb low-density lipoprotein treat hypercholesterolemia and
Its complication.For this technology compared with plasma exchange, energy is rapid, effective, a variety of autoantibodies of selective clearing, has adsorbent
Amount is big, does not lose blood plasma active ingredient, need not replace blood plasma, can avoid the advantages that pathophorous possible, and treats effect
Fruit is notable.Immunoadsorption therapy has been increasingly becoming an important branch of blood purification technology, is increasingly subject to the extensive of medical field
Concern.
At present, staphylococcus aureus protein A (SPA) immunoabsorbent column is most popular immunoabsorbent column, and SPA is
A kind of protein ingredient of some aureus cell walls, it is single chain polypeptide structure, is made up of 7~10 kinds of amino acid, no
Containing disulfide bond, molecular weight 42kD, isoelectric point 5.1.SPA amino terminal has 4 height identical Fc lands, has per area
60 or so amino acid, amino-terminal end have an active part, can combine the mankind and the immunoglobulin of other mammals
Gm3 (s+) site of CH2-CH3 residues and IgG3 in IgG1, IgG2, IgG4 Fc sections, SPA c-terminus is nonimmune ball
Protein binding area, it is right such as with beaded agarose (sepharose), silica gel covalent coupling on cross-linking to various supporting structure
Temperature, the change of pH value and the effect of denaturant are stable, are not easy depigmentation.
Except Protein A immunoadsorption post, common immunoabsorbent column also has DNA immunization adsorption column (aglucon DNA), LDL
Immunoabsorbent column (aglucon is goat-anti people LDL antibody), IgG immunoabsorbent columns (aglucon is goat anti-human igg antibody), phenylalanine/
Tryptophan immunoabsorbent column (aglucon is phenylalanine/tryptophan).
However, any adsorption column product all has the problem of aglucon comes off, its aglucon to come off is if heterologous
Material, into blood after will have security risk, come off caused by allergic reaction happen occasionally.Therefore, adsorption column product is all
Aglucon can be come off has strict quality criteria requirements.In order to control aglucon to come off, researcher is replaced by chemical coupling techniques
For physically trapping technology, or optimization and improvement by chemical coupling techniques, come off less adsorbent with obtaining aglucon.But
No matter which kind of measure, all unavoidable micro aglucons come off.Because the aglucon to come off has potential safety issue, therefore
It is necessary to continue to reduce the risk that this aglucon enters human body.
Patent CN 1830495B disclose a kind of dual column system, it is possible to reduce albumin A aglucon on Protein A immunoadsorption post
Come off.First post is Protein A immunoadsorption post, and for removing the pathogenic antibody in blood, the second post is metal-chelating filler,
The aglucon for chelating filler is metal ion, can adsorb the albumin A to be come off from the first post.But the system introduce metal from
Son is heavy metal, and many heavy metals such as Co, Ni are carcinogenic substances, and metal ion itself comes off degree and risk after coming off very
To even larger than albumin A coming off in itself.At present, aglucon can effectively and safely be reduced by, which still lacking, comes off caused risk
Method.
The content of the invention
Based on this, an object of the present invention be to provide it is a kind of can effectively reduce adsorbent aglucon come off it is combined
Adsorption column.
Concrete technical scheme is as follows.
A kind of combined adsorption column, including cylinder and the main adsorbent and additional adsorbents that are filled in the cylinder,
The main adsorbent is used to adsorb the target substance in blood, and the additional adsorbents are used to adsorb what the main adsorbent dropped
Aglucon, and the aglucon of the additional adsorbents derives from the target substance or its part.
In one of the embodiments, the aglucon of the main adsorbent is protein, polypeptide or nucleic acid.
In one of the embodiments, the albumen is staphylococcus aureus protein A, the aglucon of the additional adsorbents
For IgG.
In one of the embodiments, the albumen is anti-human LDL antibody, and the aglucon of the additional adsorbents is LDL.
In one of the embodiments, the albumen is goat anti-human igg, and the aglucon of the additional adsorbents is human IgG.
In one of the embodiments, the albumen is antibody against hepatitis B virus, and the aglucon of the additional adsorbents is hepatitis B
Antigen.
In one of the embodiments, the albumen is hepatitis aptamer, and the aglucon of the additional adsorbents resists for hepatitis
It is former.
In one of the embodiments, the cylinder includes main adsorption zone and auxiliary adsorption zone, the main adsorption zone and institute
State and aid in being provided with separation net between adsorption zone, the main adsorbent is located in the main adsorption zone, and the additional adsorbents are located at
In the auxiliary adsorption zone.
In one of the embodiments, the main adsorbent is well mixed with the additional adsorbents in the cylinder.
Another object of the present invention is to provide a kind of preparation method of combinations thereof type adsorption column.
Concrete technical scheme is as follows.
A kind of preparation method of combinations thereof type adsorption column, comprises the following steps：
By the carrier after activation and the first ligand cou, main adsorbent is prepared, first aglucon is used to adsorb in blood
Target substance；
By the carrier after activation and the second ligand cou, the additional adsorbents for adsorbing first aglucon, institute are prepared
State the second aglucon and derive from the target substance or its part；
The main adsorbent and the additional adsorbents are fitted into cylinder, obtain combined adsorption column.
A kind of combined adsorption column of the present invention and preparation method thereof has advantages below：
Main adsorbent in combined adsorption column provided by the present invention is used to remove the morbid substance in blood, and auxiliary is inhaled
Attached dose is used to adsorb the aglucon to come off from main adsorbent, is particular in that：Adsorbed based on the aglucon source of additional adsorbents
The target substance or its part that agent is adsorbed, the target substance is morbid substance, but simultaneously and humanized's material, therefore can be with
Ignore additional adsorbents aglucon come off may caused by risk.
When carrying out immunoadsorption therapy using the adsorption column, while morbid substance in effectively removing blood, Ke Yiyou
Effect reduces the aglucon to come off and enters the risk of blood, while will not introduce other risk factors.
Brief description of the drawings
Fig. 1 is the structural representation of the combined adsorption column of an embodiment；
Fig. 2 is the structural representation of the combined adsorption column of another embodiment；
Description of reference numerals
110：Main adsorbent；
120：Additional adsorbents；
130：Cylinder；
140：Separation net；
210：Main adsorbent；
220：Additional adsorbents；
230：Cylinder.
Embodiment
Below with reference to drawings and the specific embodiments, the present invention is described in further detail, but the embodiment party of the present invention
Formula is not limited to this.
Detailed description to be carried out with reference to two accompanying drawings to product below.
Fig. 1 is the combined adsorption column for main adsorbent and additional adsorbents being separated with separation net dress post of an embodiment
Structural representation.As shown in figure 1, the combined adsorption column includes cylinder 130, separation net 140 and is filled in cylinder 130
Main adsorbent 110 and additional adsorbents 120.Wherein, cylinder 130 include main adsorption zone and auxiliary adsorption zone, main adsorption zone with it is auxiliary
Help between adsorption zone and be provided with separation net 140.Main adsorbent 110 is located in main adsorption zone, and additional adsorbents 120 are located at the auxiliary
In adsorption zone.Main adsorbent 110 is used to adsorb the target substance in blood, and its aglucon can be, but not limited to be protein, such as may be used
To be staphylococcus aureus protein A or anti-human LDL antibody.The aglucon of additional adsorbents 120 falls for adsorbing main adsorbent 110
The aglucon fallen, and the aglucon of additional adsorbents 120 derives from the target substance or its part, and it is immune that can be, but not limited to
Globulin (IgG) or low-density lipoprotein (LDL).
Fig. 2 is the well mixed combined adsorption column structural representation of the main adsorbent and additional adsorbents of another embodiment
Figure.As shown in Fig. 2 combined adsorption column includes cylinder 230, and the main adsorbent 210 being filled in cylinder and auxiliary absorption
Agent 220.Main adsorbent 210 and additional adsorbents 220 are well mixed in cylinder 230.Main adsorbent 210 is used to adsorb in blood
Target substance, its aglucon can be, but not limited to be protein, such as can be that staphylococcus aureus protein A or anti-human LDL resist
Body.The aglucon of additional adsorbents 220 is used to adsorb the aglucon that main adsorbent 210 drops, and the aglucon of additional adsorbents 220 comes
The target substance or its part are come from, such as can be, but not limited to be immunoglobulin (IgG) or low-density lipoprotein (LDL).
Combined adsorption column provided by the invention can be, but not limited to be staphylococcus aureus protein A (SPA)/IgG groups
Mould assembly immunoabsorbent column, anti-human LDL antibody/combined immunoabsorbent columns of LDL, the combined immuno absorbence of goat anti-human igg/human IgG
Post, the combined immunoabsorbent column of antibody against hepatitis B virus/hepatitis B antigen, hepatitis aptamer/combined immunoabsorbent column of hepatitis C antigen,
As long as meet the inventive concept of the present invention.
The aglucon of above-mentioned additional adsorbents refers to that the aglucon of additional adsorbents can be with from target substance or its part
The target substance adsorbed with main adsorbent is same or similar, or can be with a part of identical or phase of the target substance
Seemingly, as long as the aglucon of the additional adsorbents contains binding site corresponding with the aglucon of the main adsorbent, and the bound site
Point from the target substance or has homology with target substance.Wherein, target substance refers to humanized's
Morbid substance.Therefore, the aglucon of additional adsorbents is with being directed to people or the characteristics of with humanization, the aglucon is to human body
Non-immunogenicity or only extremely low immunogenicity, meanwhile, combined adsorption column can also have good biological safety.Than
Such as, for SPA immunoabsorbent columns, the aglucon of its additional adsorbents can be human immunoglobulin(HIg) IgG or enzymolysis IgG
Obtained IgG local Fc ends (IgG is made up of Fc ends+Fab ends, and wherein there is affinity interaction at Fc ends with albumin A) or people
Work synthesizes or the Fc ends of recombination expression；For viruses adsorption post, the aglucon of its additional adsorbents can be the virus of inactivation, also may be used
Be virus part --- antigen or it is artificial synthesized or recombination expression antigen.
It is specific embodiment part below.
Embodiment 1
The present embodiment provides a kind of combined staphylococcus aureus protein A (SPA) immunoabsorbent column and reduces its absorption
Agent aglucon --- the method that " albumin A " comes off.
1st, main adsorbent --- the synthesis of SPA immunosorbent
(1) the Sepharose 4FF gel micro-balls of 10mL settling volumes are measured, with the deionized water rinsing of 20 times of volumes,
Drain, transfer the solution into 50mL ground triangular flasks, the NaOH solution for adding 7.5mL 0.6M (adds 15mg in advance
NaBH4), 7.5mL BDDEs are added, after reacting at room temperature 4h, is rinsed and drained with a large amount of water, produced
The agarose microbeads carrier of activation；
(2) 300mg recombinant protein As are added into the good agarose microbeads of above-mentioned activation, it is anti-under the conditions of pH 9.0-11.0
20h is answered, is rinsed drain with 200mL 1M NaCl solutions and a large amount of water successively, producing coupling has SPA material；
(3) material that coupling has SPA is added in 50mL triangular flasks, adds 10mL 1mol/L ethanolamine solutions (pH
9.0), 6h is reacted under the conditions of 37 DEG C.PH 4.0 acetate buffer solution, pH 8.0 Tris wash buffers, 1M is successively used again
NaCl solution is rinsed, and finally with a large amount of deionized water rinsings, produces Protein A immunoadsorption agent.
2nd, additional adsorbents --- the synthesis of IgG adsorbents
(1) the Sepharose 4FF gel micro-balls of 10mL settling volumes are measured, with the deionized water rinsing of 20 times of volumes,
Drain.Transfer the solution into 50mL ground triangular flasks, add 10mL 0.1M NaIO4Solution, react at room temperature 2h.With a large amount of
Water is rinsed and drained, and produces the agarose microbeads carrier of activation；
(2) 30mg IgG are added into the good agarose microbeads carrier of above-mentioned activation, react 12h under the conditions of pH 7.0,
Rinsed and drained with 200mL 1M NaCl solutions and a large amount of water successively, producing coupling has IgG material；
(3) have to coupling in IgG material and add a small amount of NaBH4Reduction reaction 4h is carried out, then successively uses pH 4.0 vinegar
Acid buffer, pH 8.0 Tris wash buffers, 1M NaCl solutions are rinsed, and finally with a large amount of deionized water rinsings, are produced
IgG adsorbents.
3rd, post is filled
(1) first take 2mL IgG adsorbents to be fitted into the chromatographic column with separation net, be then carefully added into 3mL albumin As again and be immunized
Adsorbent, produce adsorption column 1；
(2) 2mL IgG adsorbents and 3mL Protein A immunoadsorption agent are taken, is fitted into after both are well mixed in chromatographic column, i.e.,
Obtain adsorption column 2.
4th, aglucon, which comes off, detects experiment
Above-mentioned adsorption column No. 1 and No. 2 is taken, 1h is first rushed with 3mL/min flow velocitys in advance with physiological saline, then takes 100mL physiology
Salt solution is circulated throughout post with 2mL/min flow velocitys, after 120min, takes amount of the physiological saline as detection liquid detection split protein A, detection
Using ELISA sizing techniques, while do blank control (taking the agent of 3mL Protein A immunoadsorptions to fill post, to be operated with method).Testing result is shown in
Table 1.
The aglucon dropping situations of table 1
| The amount of coming off (pg/mL) | The amount of coming off reduces ratio | |
| Blank control | 800 | - |
| No. 1 post | 55 | 93% |
| No. 2 posts | 120 | 85% |
From table 1 it follows that the blank control group albumin A amount of coming off is 800pg/mL, and adsorption column 1 and adsorption column 2
The amount of coming off is respectively 65pg/mL and 120pg/mL, and the amount of coming off reduces about an order of magnitude, illustrates the combination that the present embodiment is provided
The aglucon that type Protein A immunoadsorption post can substantially reduce adsorbent comes off, and greatly reduces and is brought because aglucon comes off
Security risk.
5th, plasma adsorption is tested
First above-mentioned adsorption column is balanced with the equilibrium liquid (1 × PBS, pH 7.4) of at least 5 times column volumes, then with least 5 times of posts
The eluent (glycine solution of 0.1M, pH 2.5) of volume rinses pillar, then the equilibrium liquid balance columns with least 5 times column volumes
Son.Take 20mL blood plasma to cross post, flow velocity 1.7mL/min, first wash away uncombined albumen with equilibrium liquid after excessively complete blood plasma, then use eluent
Elution of bound albumen, eluting peak is collected, the protein concentration of eluting peak is detected with ultraviolet spectrophotometry, calculates the total of adhesion protein
Quality, then the absorption property of the main adsorbent of unit of account volume accordingly.
The absorption property of table 2 compares
| Absorption property (mg/mL) | |
| Blank control | 30.3 |
| No. 1 post | 30.2 |
| No. 2 posts | 30.3 |
It can be seen from the data in Table 2 that blank control group is compared with experimental group, the basic phase of absorption property of main adsorbent
Together, it is seen that the presence of additional adsorbents will not produce obvious shadow for the absorption property of main adsorbent in combinations thereof type adsorption column
Ring.
Embodiment 2
The present embodiment provides a kind of combined LDL immunoabsorbent columns and reduces the aglucon of LDL immunoabsorbent columns --- and it is " anti-human
The method that LDL antibody " comes off.
1st, main adsorbent --- the synthesis of anti-human LDL antibody mediated immunities adsorbent
(1) the Sepharose 4FF gel micro-balls of 10mL settling volumes are measured, with the deionized water rinsing of 20 times of volumes,
Drain.Transfer the solution into 50mL ground triangular flasks, add 2M Na2CO3Solution 10mL, 1g/mL CNBr acetonitrile solutions
1mL, react at room temperature 2min.Flushing is drained, and produces the agarose microbeads carrier of activation；
(2) the anti-human LDL antibody of 60mg is added into the good agarose microbeads of above-mentioned activation, it is anti-under the conditions of pH 8.0-9.0
4h is answered, flushing is drained；
(3) product of transfer step 2 (1M ethanolamine solutions, pH 9.0) into 20mL Block buffers, 2h is reacted at room temperature；
(4) reaction uses 50mL acetate buffers (0.5M NaCl solution+0.1M sodium acetate solutions, pH successively after terminating
4.0) and 50mL Tris buffer solutions (0.5M NaCl solution+0.1M Tris solution, pH 8.0) rinsing step (3) gains, extremely
Less in triplicate, finally with a large amount of deionized water rinsings, anti-human LDL antibody mediated immunities adsorbent is produced.
2nd, additional adsorbents --- the synthesis of LDL adsorbents
(1) the Sepharose 4FF gel micro-balls of 10mL settling volumes are measured, successively with volume fraction be 30%, 50%,
The 70% dioxanes aqueous solution rinses, and is finally flushed three times and is drained with anhydrous dioxanes.It is transferred into 50mL ground triangles
In bottle, 10mL NHS containing 0.1M (N- hydroxysuccinimides) and 0.1M DCC (dicyclohexylcarbodiimide) dioxanes is added
Solution, react at room temperature 2h.Reaction solution is rinsed and drained with anhydrous dioxanes and anhydrous isopropyl alcohol respectively after terminating by reaction, is produced
The agarose microbeads carrier of activation；
(2) 20mg LDL are added into the good agarose microbeads of above-mentioned activation, 2h are reacted under the conditions of pH 8.0, flushing is taken out
It is dry；
(3) product of transfer step 2 (1M ethanolamine solutions, pH 9.0) into 20mL Block buffers, reacts at room temperature
2h, then rinse and drain, produce LDL adsorbents.
3rd, post is filled
(1) first take 2mL LDL adsorbents to be fitted into the chromatographic column with separation net, then be carefully added into the anti-human LDL antibody of 3mL and exempt from
Epidemic disease adsorbent, produce adsorption column 1；
(2) 2mL LDL adsorbents and the anti-human LDL antibody mediated immunities adsorbents of 3mL are taken, loads chromatographic column after both are well mixed
In, produce adsorption column 2.
4th, aglucon comes off detection
Above-mentioned adsorption column is taken, 1h is first rushed with 3mL/min flow velocitys in advance with physiological saline, then takes 100mL physiological saline with 2mL/
Min flow velocitys are circulated throughout post, after 120min, take physiological saline to detect the amount of coming off of anti-human LDL antibody as detection liquid, detection uses
ELISA sizing techniques, while do blank control (taking the anti-human LDL antibody mediated immunities adsorbent dress posts of 3mL, operate with method), testing result
It is shown in Table 3.
The aglucon dropping situations of table 3
| The amount of coming off (ng/mL) | The amount of coming off reduces ratio | |
| Blank control group | 16 | - |
| No. 1 post | 1.4 | 91% |
| No. 2 posts | 2.6 | 84% |
From table 3 it is observed that the anti-human LDL antibody amount of coming off of blank control group is 16ng/mL, and adsorption column 1 and suction
The amount of coming off that attached column 2 is respectively 1.4ng/mL and 2.6ng/mL, and the amount of coming off reduces about an order of magnitude, illustrates the present embodiment institute
The aglucon that the combined adsorption column provided can substantially reduce adsorbent comes off, and greatly reduces and is brought because aglucon comes off
Security risk.
Each technical characteristic of embodiment described above can be combined arbitrarily, to make description succinct, not to above-mentioned reality
Apply all possible combination of each technical characteristic in example to be all described, as long as however, the combination of these technical characteristics is not deposited
In contradiction, the scope that this specification is recorded all is considered to be.
Embodiment described above only expresses the several embodiments of the present invention, and its description is more specific and detailed, but simultaneously
Can not therefore it be construed as limiting the scope of the patent.It should be pointed out that come for one of ordinary skill in the art
Say, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to the protection of the present invention
Scope.Therefore, the protection domain of patent of the present invention should be determined by the appended claims.
Claims (2)
1. a kind of combined adsorption column, it is characterised in that including cylinder and the main adsorbent being filled in the cylinder and auxiliary
Adsorbent is helped, the main adsorbent is used to adsorb the target substance in blood, and the additional adsorbents are used to adsorb the main suction
The attached dose of aglucon to drop, and the aglucon of the additional adsorbents derives from the target substance or its part；The main adsorbent
For staphylococcus aureus protein A, the aglucon of the additional adsorbents is IgG；The main adsorbent and the additional adsorbents
It is supported on the agarose gel microsphere carrier through different activation process；
The main adsorbent is well mixed with the additional adsorbents in the cylinder.
2. a kind of preparation method of combined adsorption column, it is characterised in that comprise the following steps：
By the carrier after activation and the first ligand cou, main adsorbent is prepared, first aglucon is used to adsorb the mesh in blood
Mark material；
By the carrier after activation and the second ligand cou, the additional adsorbents for adsorbing first aglucon are prepared, described
Two aglucons derive from the target substance or its part；
It is fitted into after the main adsorbent and the additional adsorbents are well mixed in cylinder, obtains combined adsorption column.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510595440.0A CN105214341B (en) | 2015-09-17 | 2015-09-17 | combined adsorption column and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510595440.0A CN105214341B (en) | 2015-09-17 | 2015-09-17 | combined adsorption column and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105214341A CN105214341A (en) | 2016-01-06 |
| CN105214341B true CN105214341B (en) | 2017-12-15 |
Family
ID=54983823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510595440.0A Active CN105214341B (en) | 2015-09-17 | 2015-09-17 | combined adsorption column and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105214341B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106669630A (en) * | 2016-12-29 | 2017-05-17 | 珠海健帆生物科技股份有限公司 | Enveloped DNA immunosorbent and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1830495B (en) * | 2005-03-11 | 2010-12-15 | 广东天普生化医药股份有限公司 | Blood purification method and system based on affinity absorption |
| CN101185880B (en) * | 2007-08-22 | 2010-05-19 | 大连理工大学 | Blood purification adsorption agent for clearing antibody and preparation method thereof |
| US8053565B2 (en) * | 2009-05-28 | 2011-11-08 | Bio-Rad Laboratories, Inc. | Multi-media affinity column to prevent leaching of ligands |
| CN102660569B (en) * | 2012-04-21 | 2013-11-06 | 大连理工大学 | Method for preparing recombinant human IgE receptor protein and application of recombinant human IgE receptor protein |
| US20160024144A1 (en) * | 2013-03-14 | 2016-01-28 | Amgen Inc. | Removal of leaked affinity purification ligand |
-
2015
- 2015-09-17 CN CN201510595440.0A patent/CN105214341B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105214341A (en) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boschetti | The use of thiophilic chromatography for antibody purification: a review | |
| ES2793176T3 (en) | Affinity Chromography Matrix | |
| CN105899235B (en) | Method for purifying the antibody-drug conjugates of CYS connection | |
| CA1073815A (en) | Method for purification and isolation of hepatitis virus for use in the preparation of vaccine | |
| EP2058335B1 (en) | Biocompatible three dimensional matrix for the immobilization of biological substances | |
| CN107486176A (en) | A kind of sorbing material for blood purification and preparation method thereof | |
| JPH0787966A (en) | Cytotoxin and its application | |
| JPH09508976A (en) | Sterile and pyrogen-free column with bound proteins for binding and removing substances in blood | |
| Kang et al. | Cyclic peptide ligand with high binding capacity for affinity purification of immunoglobulin G | |
| CN103212377A (en) | Preparation method of agarose immune magnetic microspheres and applications thereof | |
| WO2021109177A1 (en) | Immunoglobulin binding protein, preparation method and application thereof | |
| JP2019504060A (en) | Method for isolating monoclonal antibody isoforms | |
| CN103179987A (en) | Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein | |
| CN110026166A (en) | It is a kind of for targeting the albumin A adsorbent material and preparation method thereof of absorption | |
| CN103611504B (en) | A kind of sorbing material for blood perfusion removal rheumatoid factor and preparation method thereof | |
| CN105214341B (en) | combined adsorption column and preparation method thereof | |
| FR3008097A1 (en) | AFFINITY CHROMATOGRAPHY MATRIX | |
| CN107754764A (en) | A kind of protein A immunoadsorption material of high carrying capacity and preparation method thereof | |
| Xu et al. | Development of histidine-tagged cyclic peptide functionalized monolithic material for the affinity purification of antibodies in biological matrices | |
| CN106220730A (en) | A kind of preparation method of Aspergillus fumigatus galactomannan polyclonal antibody | |
| CN103111270B (en) | Adsorbing material of hepatitis B antigen protein and preparation method of material | |
| Yao et al. | Nanobody-loaded immunosorbent for highly-specific removal of interleukin-17A from blood | |
| JP2012001462A (en) | Column for antibody purification | |
| TW200927254A (en) | Antibody production method | |
| JPH03505287A (en) | Biocompatible, substance-specific reagents for processing physiological fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510660 No. 8 Shenzhou street, Science City, Guangzhou hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee after: Guangzhou Kangsheng Biotechnology Co., Ltd Address before: 510660 No. 8 Shenzhou street, Science City, Guangzhou hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee before: Guangzhou Kang Huai Biology Science and Technology Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |